Tenaya Therapeutics
Tenaya Therapeutics develops gene therapies and precision medicines for heart disease, founded by leading cardiovascular scientists.
Company Overview
Tenaya Therapeutics develops gene therapies and precision medicines targeting heart disease. Founded by leading cardiovascular scientists, the company advances a pipeline of investigational therapeutics for heart conditions. Tenaya Therapeutics engages in collaborations with academic institutions like Gladstone Institutes and University of Texas Southwestern Medical Center.
Therapeutic Platforms
Tenaya Therapeutics utilizes three product platforms to address heart disease: Gene Therapy, Cellular Regeneration, and Precision Medicine. These platforms are central to the company's efforts to develop innovative treatments for various heart conditions. These approaches are designed to address the root causes of heart disease at a molecular and cellular level.
Research and Development Initiatives
Tenaya Therapeutics has a dedicated in vivo pharmacology group and a vivarium for developing disease models. The company focuses on advancing a pipeline of investigational therapeutics, with key programs like TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The company also offers expanded access programs for its investigational treatments.
Cardiac Genetic Medicines Manufacturing Center
Tenaya Therapeutics has established the Cardiac Genetic Medicines Manufacturing Center for the production of gene therapies. This center underscores the company's commitment to ensuring a steady and reliable supply of high-quality therapeutic products to support its clinical and research activities.
FDA Designations and Clinical Trials
The FDA has granted Orphan Drug Designation to Tenaya Therapeutics' TN-401 for PKP2-associated ARVC. The company is conducting clinical trials for investigational treatments, including TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC. These designations and trials are vital steps toward making novel treatments available to patients with critical heart conditions.